The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.

Article  Google Scholar 

Byrne RA, Rossello X, Coughlan JJ, et al. ESC Scientific Document Group: 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720–826. https://doi.org/10.1093/eurheartj/ehad191.

Article  PubMed  CAS  Google Scholar 

De Servi S, Landi A, Savonitto S, et al. Tailoring oral antiplatelet therapy in acute coronary syndromes: from guidelines to clinical practice. J Cardiovasc Med. 2023;24:77–86.

Article  Google Scholar 

Valgimigli M, Gragnano F, Branca M, et al. Ticagrelor or clopidogrel monotherapy vs dual antiplatelet therapy after percutaneous coronary intervention: a systematic review and patient-level meta-analysis. JAMA Cardiol. 2024;9:437–48.

Article  PubMed  Google Scholar 

Gragnano F, Mehran R, Branca M, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions. J Am Coll Cardiol. 2023;81:537–52.

Article  PubMed  CAS  Google Scholar 

Virani SS, Newby LK, Arnold SV, Peer Review Committee Members. CAPRIE Steering Committee, et al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–39. https://doi.org/10.1016/s0140-6736(96)09457-3.

Article  Google Scholar 

Gragnano F, Cao D, Pirondini L, et al. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol. 2023;82:89–105.

Article  PubMed  CAS  Google Scholar 

AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148:e9-e119. https://doi.org/10.1161/CIR.0000000000001168

Kang J, Park KW, Lee H, et al. Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study. Circulation. 2023;147:108–17. https://doi.org/10.1161/CIRCULATIONAHA.122.062770.

Article  PubMed  CAS  Google Scholar 

Watanabe H, Morimoto T, Natsuaki M, STOPDAPT-2 investigators, et al. Clopidogrel vs aspirin monotherapy beyond 1 year after percutaneous coronary intervention. J Am Coll Cardiol. 2024;83:17–31.

Article  PubMed  CAS  Google Scholar 

Cattaneo M. New P2Y(12) inhibitors. Circulation. 2010;121:171–9. https://doi.org/10.1161/CIRCULATIONAHA.109.853069.

Article  PubMed  Google Scholar 

Tan DS, Aw JWX, Winther M, Goh LL, Ong HY, Wee E, Liu J, Ho HK. CYP2C19 phenotype in South-East Asian acute coronary syndrome patients and impact on major adverse cardiovascular events. J Clin Pharm Ther. 2020;45:52–8.

Article  PubMed  CAS  Google Scholar 

De Servi S, Landi A, Savonitto S. Antiplatelet therapy in elderly patients with acute coronary syndromes: the clopidogrel revenge: possible reasons for a bright comeback. Cardiovasc Drugs Ther. 2021;35(2):399–401. https://doi.org/10.1007/s10557-020-07055-0.

Article  PubMed  Google Scholar 

De Servi S, Landi A, Savonitto S. Clopidogrel induced reduction in neutrophil count: an overlooked beneficial effect? Eur J Intern Med. 2024;124:32–4. https://doi.org/10.1016/j.ejim.2024.03.026.

Article  PubMed  CAS  Google Scholar 

Nelson TA, Parker WAE, GhukasyanLakic T, et al. Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. Platelets. 2022;33:425–31. https://doi.org/10.1080/09537104.2021.1934667.

Article  PubMed  CAS  Google Scholar 

Palmerini T, Barozzi C, Tomasi L, et al. A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study. Thromb Res. 2010;125:309–14. https://doi.org/10.1016/j.thromres.2009.06.016.

Article  PubMed  CAS  Google Scholar 

Xiao Z, Théroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol. 2004;43:1982–8.

Article  PubMed  CAS  Google Scholar 

Soehnlein O, Döring Y. Beyond association: high neutrophil counts are a causal risk factor for atherosclerotic cardiovascular disease. Eur Heart J. 2023;44:4965–7. https://doi.org/10.1093/eurheartj/ehad711.

Article  PubMed  Google Scholar 

Adamstein NH, MacFadyen JG, Rose LM, et al. The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. Eur Heart J. 2021;42:896–903. https://doi.org/10.1093/eurheartj/ehaa1034.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Howard C, Noe A, Skerjanec A, Holzhauer B, Wernsing M, Ligueros-Saylan M, Thuren T. Safety and tolerability of canakinumab, an IL-1beta inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies. Cardiovasc Diabetol. 2014;13:94. https://doi.org/10.1186/1475-2840-13-94.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Valgimigli M, Aboyans V, Angiolillo D, et al. Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease. Eur Heart J Cardiovasc Pharmacother. 2023;9(5):462–96. https://doi.org/10.1093/ehjcvp/pvad032.

Article  PubMed  Google Scholar